KER-012
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Keros Therapeutics
Keros Therapeutics is a clinical-stage biotech focused on developing engineered ligand traps to modulate the TGF-β signaling pathway for serious disorders in hematology, pulmonary, and cardiovascular diseases. The company has advanced its lead asset, KER-050, into Phase 2 trials for myelodysplastic syndromes and myelofibrosis, and its second candidate, KER-012, into Phase 2 for pulmonary arterial hypertension and cardiovascular disorders. Its strategy leverages a selective, platform-based approach to target specific ligands within the TGF-β superfamily, aiming to improve therapeutic outcomes with potentially better safety profiles. Keros went public in 2020 and is building a compelling clinical data package to validate its technology.
View full company profileAbout Keros Therapeutics
Keros Therapeutics is a clinical-stage biotech focused on developing engineered ligand traps to modulate the TGF-β signaling pathway for serious disorders in hematology, pulmonary, and cardiovascular diseases. The company has advanced its lead asset, KER-050, into Phase 2 trials for myelodysplastic syndromes and myelofibrosis, and its second candidate, KER-012, into Phase 2 for pulmonary arterial hypertension and cardiovascular disorders. Its strategy leverages a selective, platform-based approach to target specific ligands within the TGF-β superfamily, aiming to improve therapeutic outcomes with potentially better safety profiles. Keros went public in 2020 and is building a compelling clinical data package to validate its technology.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia | Approved |
| LIQ861 (treprostinil) inhalation powder | Liquidia | Phase 3 |
| L606 (liposomal treprostinil) injection | Liquidia | Preclinical |
| NTP42 | ATXA Therapeutics | Phase 1 |
| Transdermal Treprostinil Prodrug Patch | Corsair Pharma | Pre-clinical |
| Anti-EMAP II monoclonal antibody | Allinaire Therapeutics | Pre-clinical |
| Tiprelestat | tiakis Biotech | Phase 2 |
| Seralutinib | Chiesi | Phase 3 |
| Sotatercept | Merck | Phase 3 |
| TPIP (Treprostinil Palmitil Inhalation Powder) | Insmed | Phase 2b |
| Ralinepag | United Therapeutics | Phase 3 |
| Beraprost MR | United Therapeutics | Phase 3 |